{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:20:04Z","timestamp":1790140804563,"version":"4.0.1"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Choosing between endovascular and open (bypass) surgical revascularization for chronic limb-threatening ischemia has major implications for clinical practice.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the cost-effectiveness of endovascular vs bypass surgical revascularization.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This economic evaluation used individual-level data from the Best Endovascular vs Best Surgical Therapy for Patients With Chronic Limb Ischemia (BEST-CLI) trial, with the first patient enrolled August 28, 2014, and the final October 18, 2019, for a median follow-up of 2.7 years. An individual-level, continuous-time Markov model with health states based on adjudicated clinical events from BEST-CLI was developed. Rates of clinical outcomes, health utilities, and health care resource use were derived from trial data. Unit costs came from Medicare insurance claims data and the physician fee schedule. The data were analyzed between June 27, 2025, and May 28, 2026.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcomes were incremental cost per life-years gained, incremental quality-adjusted life-years (QALYs) gained, incremental net monetary benefit, and cost per major events of revascularization and amputation avoided over a 5- and 10-year time horizon. One-way and probabilistic sensitivity analyses were performed to quantify uncertainty.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The cohort included 1434 patients from BEST-CLI (mean [SD] age, 67 [10] years; 1026 male [71.5%]). In the base case analysis, over a 5-year time horizon, the mean per-person direct medical costs were $118\u202f559 (95% credible interval [CrI], $86\u202f978-$157\u202f152) for bypass surgery and $125\u202f535 (95% CrI, $96\u202f205-$160\u202f357) for endovascular surgery. The mean survival per person was 3.84 years (95% CrI, 3.74-3.93 years) and 3.78 years (95% CrI, 3.61-3.94 years) for bypass and endovascular surgery, respectively. The mean QALYs per person were 2.53 (95% CrI, 2.34-2.70) for bypass surgery and 2.48 (95% CrI, 2.28-2.67) for endovascular surgery. Bypass surgery dominated endovascular surgery with respect to both costs per life-year and per QALY gained. The results over 10 years were consistent with those of the 5-year BEST-CLI follow-up. In the Monte Carlo simulation, there was a 93% chance that bypass surgery was more cost-effective than endovascular surgery.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cost-effectiveness study found that bypass surgery was more cost-effective in most probabilistic simulations; however, uncertainty remained, highlighting the need for future research to identify subgroups in whom each approach may be cost-effective.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.27335","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:00:20Z","timestamp":1785855620000},"page":"e2627335","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness of Endovascular vs Open Surgery for Chronic Limb-Threatening Ischemia"],"prefix":"10.1001","volume":"9","author":[{"given":"Zafar","family":"Zafari","sequence":"first","affiliation":[{"name":"University of Maryland Institute for Health Computing, Bethesda"},{"name":"Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Najafzadeh","sequence":"additional","affiliation":[{"name":"Medidata Solutions, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mufaddal","family":"Mahesri","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HoJin","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip P.","family":"Goodney","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Conte","sequence":"additional","affiliation":[{"name":"Division of Vascular and Endovascular Surgery, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Creager","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Dake","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, University of Arizona Health Sciences, Tucson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Powell","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J.","family":"White","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, The Ochsner Clinical School, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Strong","sequence":"additional","affiliation":[{"name":"Division of Vascular and Endovascular Surgery, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Rosenfield","sequence":"additional","affiliation":[{"name":"Section of Vascular Medicine and Intervention, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alik","family":"Farber","sequence":"additional","affiliation":[{"name":"Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Menard","sequence":"additional","affiliation":[{"name":"Division of Vascular and Endovascular Surgery, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niteesh K.","family":"Choudhry","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"zoi260754r1","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1016\/j.jvs.2019.02.016","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia.","volume":"69","author":"Conte","year":"2019","journal-title":"J Vasc Surg"},{"issue":"9901","key":"zoi260754r2","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis.","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"issue":"16","key":"zoi260754r3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009724","article-title":"Determinants of long-term outcomes and costs in the management of critical limb ischemia: a population-based cohort study.","volume":"7","author":"Mustapha","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"zoi260754r4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1056\/NEJMcp1709326","article-title":"Chronic limb-threatening ischemia.","volume":"379","author":"Farber","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi260754r5","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa2207899","article-title":"Surgery or endovascular therapy for chronic limb-threatening ischemia.","volume":"387","author":"Farber","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"zoi260754r6","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1161\/CIRCULATIONAHA.123.065277","article-title":"Quality of life in patients with chronic limb-threatening ischemia treated with revascularization.","volume":"149","author":"Menard","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"zoi260754r8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"11","key":"zoi260754r11","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s40273-019-00827-z","article-title":"Developing open-source models for the US health system: practical experiences and challenges to date with the Open-Source Value Project.","volume":"37","author":"Jansen","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"zoi260754r12","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1016\/j.jvs.2023.03.253","article-title":"Outcomes and costs of lower extremity peripheral vascular interventions with intravascular ultrasound.","volume":"77","author":"Brahmandam","year":"2023","journal-title":"J Vasc Surg"},{"issue":"1","key":"zoi260754r13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1001\/jamasurg.2013.4277","article-title":"Relationship between regional spending on vascular care and amputation rate.","volume":"149","author":"Goodney","year":"2014","journal-title":"JAMA Surg"},{"issue":"6","key":"zoi260754r15","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1097\/01.CCM.0000164543.14619.00","article-title":"Daily cost of an intensive care unit day: the contribution of mechanical ventilation.","volume":"33","author":"Dasta","year":"2005","journal-title":"Crit Care Med"},{"issue":"5","key":"zoi260754r17","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jamainternmed.2020.7372","article-title":"Payment for dialysis services in the individual market.","volume":"181","author":"Trish","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"3","key":"zoi260754r19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.123.009999","article-title":"Cost of cardiovascular disease event and cardiovascular disease treatment-related complication hospitalizations in the United States.","volume":"17","author":"Tajeu","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"5","key":"zoi260754r22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group.","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"issue":"10","key":"zoi260754r23","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"zoi260754r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2026.02.018","article-title":"Open versus endovascular revascularisation for femoropopliteal disease in patients with chronic limb threatening ischaemia.","author":"Conte","year":"2026","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"5","key":"zoi260754r25","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jvs.2024.05.049","article-title":"Surgery or endovascular therapy for patients with chronic limb-threatening ischemia requiring infrapopliteal interventions.","volume":"80","author":"Giles","year":"2024","journal-title":"J Vasc Surg"},{"issue":"22","key":"zoi260754r26","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1016\/j.jcin.2016.08.036","article-title":"Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: results from the IN.PACT SFA II trial.","volume":"9","author":"Salisbury","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"zoi260754r27","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jcin.2021.01.004","article-title":"Use of atherectomy during index peripheral vascular interventions.","volume":"14","author":"Hicks","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"zoi260754r28","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40273-014-0179-1","article-title":"Network vs. pairwise meta-analyses: a case study of the impact of an evidence-synthesis paradigm on value of information outcomes.","volume":"32","author":"Zafari","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"9501","key":"zoi260754r30","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/S0140-6736(05)67704-5","article-title":"Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial.","volume":"366","author":"Adam","year":"2005","journal-title":"Lancet"},{"key":"zoi260754r31","doi-asserted-by":"publisher","first-page":"43S","DOI":"10.1016\/j.jvs.2010.01.076","article-title":"Bypass Versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis.","volume":"51","author":"Forbes","year":"2010","journal-title":"J Vasc Surg"},{"issue":"65","key":"zoi260754r32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/YTFV4524","article-title":"Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT.","volume":"28","author":"Moakes","year":"2024","journal-title":"Health Technol Assess"},{"issue":"7","key":"zoi260754r33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.22138","article-title":"Geographical variation in health spending across the US among privately insured individuals and enrollees in Medicaid and Medicare.","volume":"5","author":"Cooper","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi260754r34","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jvs.2020.06.050","article-title":"Defining the 90-day cost structure of lower extremity revascularization for alternative payment model assessment.","volume":"73","author":"Duwayri","year":"2021","journal-title":"J Vasc Surg"},{"issue":"10","key":"zoi260754r35","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.amjcard.2018.08.018","article-title":"Comparison of outcomes and cost of endovascular management versus surgical bypass for the management of lower extremities peripheral arterial disease.","volume":"122","author":"Doshi","year":"2018","journal-title":"Am J Cardiol"},{"key":"zoi260754r36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.avsg.2017.01.027","article-title":"Treating peripheral artery disease in the wake of rising costs and protracted length of stay.","volume":"44","author":"Wang","year":"2017","journal-title":"Ann Vasc Surg"},{"issue":"4","key":"zoi260754r37","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1377\/hlthaff.2021.01476","article-title":"Trends in hospital prices paid by private health plans varied substantially across the US.","volume":"41","author":"Levinson","year":"2022","journal-title":"Health Aff (Millwood)"},{"key":"zoi260754r7","unstructured":"Best endovascular vs best surgical therapy in patients with critical limb ischemia (BEST-CLI). ClinicalTrials.gov identifier: NCT02060630. Updated April 11, 2023. Accessed September 21, 2025. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02060630"},{"key":"zoi260754r9","unstructured":"Incerti? D, Jansen? JP, Clements? M; R Core Team. hesim: Health economic simulation modeling and decision analysis. The Comprehensive R Network. 2024. Accessed March 15, 2025. https:\/\/cran.r-project.org\/web\/packages\/hesim\/index.html"},{"key":"zoi260754r10","unstructured":"Incerti? D, Jansen? JP. hesim: Health economic simulation modeling and decision analysis.? arXiv. Preprint posted online February 18, 2021. https:\/\/arxiv.org\/abs\/2102.09437"},{"key":"zoi260754r14","unstructured":"Hospital expenses per adjusted inpatient day. Kaiser Family Foundation. Accessed July 29, 2024. https:\/\/www.kff.org\/health-costs\/state-indicator\/expenses-per-inpatient-day\/"},{"key":"zoi260754r16","unstructured":"Mirel? LB, Carper? K. Trends in health care expenditures for the elderly, age 65 and older: 2001, 2006, and 2011. In: Statistical Brief (Medical Expenditure Panel Survey (US)). Agency for Healthcare Research and Quality; 2001. Accessed June 14, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK476262\/"},{"key":"zoi260754r18","unstructured":"PFS look-up tool. Centers for Medicare & Medicaid Services. Accessed July 29, 2024. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search\/overview"},{"key":"zoi260754r20","unstructured":"Table 2.4.4.U. price indexes for personal consumption expenditures by type of product. Bureau of Economic Analysis. Accessed May 24, 2026. https:\/\/apps.bea.gov\/iTable\/?reqid=19&step=2&isuri=1&categories=underlying#eyJhcHBpZCI6MTksInN0ZXBzIjpbMSwyLDNdLCJkYXRhIjpbWyJjYXRlZ29yaWVzIiwiU3VydmV5Il0sWyJOSVBBX1RhYmxlX0xpc3QiLCIyMDE2Il1dfQ=="},{"key":"zoi260754r21","unstructured":"EQ-5D-5L. EuroQol. Accessed March 17, 2025. https:\/\/euroqol.org\/information-and-support\/euroqol-instruments\/eq-5d-5l\/"},{"key":"zoi260754r29","unstructured":"Childers? CP, Lamaina? M, Liu? C, . Cost-Effectiveness of Leg Bypass Versus Endovascular Therapy for Critical Limb Ischemia: A Systematic Review. Department of Veterans Affairs; 2019. Accessed June 17, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK543445\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2852419\/zafari_2026_oi_260754_1785249911.81768.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:00:22Z","timestamp":1785855622000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2852419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.27335","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]}}}